Top Page
Starpharma Holdings Limited
(OTC:SPL)
Starpharma Holdings Limited (SPL) vs. iShares MSCI Australia ETF (EWA)
Starpharma Holdings Limited Business Overview & Revenue Model
Starpharma Holdings Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.85M | 4.91M | 8.29M | 2.94M | 4.68M | 1.80M |
| Gross Profit | -3.73M | 3.69M | 7.66M | 1.22M | 1.91M | 539.50K |
| EBITDA | -9.72M | -10.93M | -9.63M | -22.08M | -22.34M | -26.05M |
| Net Income | -9.99M | -9.99M | -8.16M | -15.64M | -16.15M | -19.73M |
Balance Sheet | ||||||
| Total Assets | 25.42M | 25.42M | 36.81M | 52.09M | 66.17M | 73.24M |
| Cash, Cash Equivalents and Short-Term Investments | 15.41M | 15.41M | 23.36M | 35.18M | 49.92M | 60.50M |
| Total Debt | 2.40M | 2.40M | 3.53M | 8.27M | 8.19M | 1.17M |
| Total Liabilities | 6.42M | 6.42M | 8.70M | 17.27M | 17.78M | 10.94M |
| Stockholders Equity | 19.00M | 19.00M | 28.12M | 34.81M | 48.39M | 62.30M |
Cash Flow | ||||||
| Free Cash Flow | -6.80M | -6.80M | -7.07M | -14.15M | -14.00M | -15.05M |
| Operating Cash Flow | -6.76M | -6.76M | -6.98M | -13.53M | -13.16M | -14.81M |
| Investing Cash Flow | -42.00K | -42.00K | -89.00K | -610.00K | -836.00K | -246.00K |
| Financing Cash Flow | -1.13M | -1.13M | -4.75M | -695.00K | 3.23M | 46.30M |
Starpharma Holdings Limited Technical Analysis
Starpharma Holdings Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$47.32M | -4.95 | -49.72% | ― | ― | 10.78% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$169.38M | ― | -41.51% | ― | -40.74% | -21.21% | |
47 Neutral | AU$109.49M | -19.03 | -90.37% | ― | ― | 26.38% | |
46 Neutral | AU$22.04M | ― | -143.71% | ― | 306.88% | ― | |
43 Neutral | AU$59.36M | ― | -138.54% | ― | ― | 16.61% | |
36 Underperform | AU$26.89M | -5.51 | -157.93% | ― | ― | -36.89% |
Starpharma Holdings Limited Corporate Events
Starpharma Holdings Limited has announced significant progress in its strategic initiatives during the first quarter of FY26, highlighted by two major partnership agreements. The company signed a collaboration and license agreement with Genentech, a member of the Roche Group, for the development of DEP® cancer therapies, securing an upfront payment of USD $5.5 million and potential milestone payments up to USD $564 million. Additionally, a research and option agreement with Radiopharm Theranostics was established to develop a novel radiotherapy asset, marking Starpharma’s first radiopharmaceutical partnership. These agreements reflect growing industry validation of Starpharma’s DEP® platform, enhancing its commercial traction and positioning within the biotechnology sector. The company also received a $3.7 million R&D tax incentive refund and reported a cash balance of $14.3 million at the end of September 2025. Starpharma remains focused on advancing its DEP® HER2 radiopharmaceuticals program, expanding partnerships, and driving revenue growth through licensing and product sales.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited has received an upfront payment of USD $5.5 million from Genentech as part of a recently announced license agreement. This collaboration will utilize Starpharma’s proprietary DEP® platform technology to develop dendrimer-drug conjugates incorporating Genentech medicines for oncology targets. The agreement positions Starpharma to potentially receive up to USD $564 million in development, commercial, and net sales milestones, alongside tiered royalties on global net sales. This partnership enhances Starpharma’s industry positioning by leveraging its advanced dendrimer technology to expand its product offerings and market reach in oncology.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited, a leader in dendrimer technology, presented at the Australian Microcap Investment Conference, highlighting its strategic focus on transforming drug delivery in oncology through its DEP® platform. The company is advancing its pipeline of novel assets, particularly in radiopharmaceuticals, and has secured strategic partnerships with major biotech firms like Genentech and Radiopharm Theranostics. These collaborations underscore the platform’s potential and are expected to expand commercial opportunities significantly. Key developments in the coming year include progressing radiotheranostics to clinical trials, expanding partnerships, and increasing revenue from licensing and product sales.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited announced a change in the director’s interest, with Robert B. Thomas acquiring 450,000 ordinary shares through an on-market purchase. This transaction increases his direct holding to 950,000 shares, reflecting a significant personal investment in the company, which could signal confidence in the company’s future prospects.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited has announced its 2025 Annual General Meeting, scheduled for November 14, 2025, which will be held in a hybrid format allowing both in-person and remote participation. The Board recommends shareholders vote in favor of all resolutions, emphasizing the importance of shareholder engagement and participation in the company’s strategic decisions.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Starpharma Holdings Limited announced a change in the director’s interest notice, revealing that Cheryl Maley, a director, has experienced a lapse of 439,752 performance rights due to unmet performance criteria. This adjustment in director’s interests reflects internal performance evaluations and may impact the company’s governance and stakeholder confidence.
The most recent analyst rating on (AU:SPL) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Starpharma Holdings Limited stock, see the AU:SPL Stock Forecast page.
Radiopharm Theranostics has entered into a research and option agreement with Starpharma to develop a novel radiopharmaceutical molecule using Starpharma’s DEP® platform. This collaboration marks a significant milestone for both companies, potentially enhancing Radiopharm’s cancer treatment offerings and demonstrating the applicability of Starpharma’s technology in targeted cancer therapies. The agreement includes an exclusive option for Radiopharm to license the developed asset, with significant financial terms tied to successful development and commercialization.
Starpharma has entered into a research and option agreement with Radiopharm Theranostics to develop a novel radiotherapy asset using its proprietary DEP® platform technology. This partnership is a significant milestone for Starpharma, marking its first radiopharmaceutical collaboration and the advancement of its Star Navigator program into a formal research collaboration. The agreement allows Starpharma to receive R&D service and manufacturing fees, with the potential for substantial financial gains through licensing options, success-based milestones, and royalties. This collaboration highlights the potential of dendrimers in radiopharmaceutical drug development and expands Starpharma’s commercial opportunities without impacting its internal development efforts.
Starpharma Holdings Limited has announced a significant collaboration and license agreement with Genentech, part of the Roche Group. This partnership will leverage Starpharma’s DEP® platform to develop dendrimer-drug conjugates targeting specific oncology areas. The agreement includes an upfront payment of USD $5.5 million, with potential success-based milestones totaling up to USD $564 million. Additionally, Starpharma stands to earn tiered royalties on the global net sales of any resulting products, marking a substantial opportunity for growth and industry positioning.
Starpharma Holdings Limited has entered into a collaboration and license agreement with Genentech, a Roche Group member, to develop cancer therapies using Starpharma’s DEP® technology. This partnership will see Starpharma receive an upfront payment and potential milestone payments totaling up to USD $564 million, along with royalties on global sales. The collaboration highlights Starpharma’s strategic focus on forming impactful partnerships to expand its market reach and enhance therapeutic offerings, positioning the company strongly within the oncology sector.
Starpharma Holdings Limited announced that its 2025 Annual General Meeting will be held on November 14, 2025, in Melbourne. The announcement highlights the company’s ongoing commitment to transparency and stakeholder engagement, with the Chair’s address and CEO’s presentation to be released to the market prior to the meeting. This meeting is an opportunity for the company to discuss its strategic direction and operational updates, potentially impacting its market positioning and stakeholder relations.
Starpharma Holdings Limited has received a $3.7 million R&D Tax Incentive refund for the 2025 financial year under the Australian Federal Government’s program. This incentive is crucial for Starpharma as it continues to invest in high-impact R&D programs, strengthening its position in the global biotechnology sector and supporting the advancement of its dendrimer technology towards commercialization and global patient benefit.
Starpharma Holdings Limited has released its corporate governance statement for the financial year ending June 30, 2025, which is available on their website. The statement confirms the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, highlighting their commitment to transparency and accountability. This release underscores Starpharma’s dedication to maintaining high governance standards, potentially reinforcing stakeholder confidence and supporting its strategic objectives in the competitive biotechnology market.
Starpharma Holdings Limited reported a significant increase in revenue for the fiscal year ending June 30, 2025, with a 183% rise to $4.9 million, driven by research revenue and increased sales of Viraleze™ and VivaGel® BV. The company also reduced its reported loss by 31% to $10 million, reflecting decreased research and product development expenditures. These financial results indicate a positive trajectory for Starpharma, enhancing its position in the biotechnology industry and potentially benefiting stakeholders through improved financial performance and strategic growth.
Starpharma Holdings Limited’s 2025 Annual Report highlights the company’s commitment to delivering meaningful patient outcomes through its advanced dendrimer technology. The report outlines key focus areas including maximizing the value of its DEP® platform, accelerating early asset development, and building long-term sustainability, which are crucial for enhancing the company’s operations and industry positioning.
Starpharma Holdings Limited reported a 41% decline in revenue to $4.912 million for the year ending June 30, 2025, compared to the previous year. However, when excluding a one-time settlement from the prior year, adjusted revenue increased by 183%, driven by research revenue from Petalion Therapeutics and increased sales of Viraleze™ and VivaGel® BV. The company’s loss for the period rose by 22% to $9.99 million, though adjusted loss decreased by 32% due to reduced research and product development expenses. The financial results reflect ongoing investment in research and development, particularly in the DEP® drug delivery programs, which are crucial for the company’s strategic growth and industry positioning.